Nasdaq · CIK 0001636282 · PHARMACEUTICAL PREPARATIONS
SPYRE THERAPEUTICS, INC.
SYRE chart by TradingView
PRICE HISTORY
LIVE · NASDAQSYRE chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $0.0B
- EBITDA
- $-0.2B
- FREE CASH FLOW
- —
- EPS
- —
- GROSS MARGIN
- —
- ROIC
- —
Q4 FY24ENDED DEC 2024HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 33 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
—
⤢
P / SALES (TTM)
—
+5935%5.9x2013.0x
⤢
P / BOOK
2.3x
-40%0.5x9.1x
⤢
EV / EBITDA (TTM)
—
⤢
EV / REVENUE (TTM)
—
⤢
FCF YIELD (TTM)
—
-180.1pp-200.73%-9.03%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$0.0B
+$0.0B⤢
EBITDA (DERIVED)
$-0.1B
$0.1B⤢
NET INCOME
$-0.1B
$0.1B⤢
EPS (DILUTED)
$-1.11
+$1.50⤢
REVENUE GROWTH YOY
—
-40.1pp-100.00%60.78%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
—
-10684.4pp-10797.62%14.98%
⤢
RETURN ON CAPITAL
—
⤢
RETURN ON EQUITY (TTM)
-40.17%
-16.7pp-239.20%-23.51%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN—
OPERATING MARGIN—
NET MARGIN—
FCF MARGIN—
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
—
$0.0B⤢
STOCK-BASED COMP
$0.0B
+24153%⤢
CAPITAL EXPENDITURE
—
-100%⤢
SHARES OUTSTANDING
0.05B
+1838%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.1B
+104%⤢
TOTAL DEBT
—
⤢
DEBT / EBITDA (TTM)
—
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 94.82%INSIDERS 5.74%OTHER / RETAIL 0.00%304 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| FMR, LLC | 13.40% | 11.8M | $1.24B | +1.2% |
| Blackrock Inc. | 6.28% | 5.5M | $579.2M | -0.0% |
| RTW Investments LP | 4.74% | 4.2M | $437.7M | +0.0% |
| Fairmount Funds Management LLC | 4.57% | 4.0M | $421.5M | +0.0% |
| Perceptive Advisors Llc | 4.30% | 3.8M | $396.9M | +23.3% |
| Venrock Adviser, LLC | 4.19% | 3.7M | $386.6M | +0.0% |
| Vanguard Capital Management LLC | 3.48% | 3.1M | $320.8M | NEW |
| Driehaus Capital Management, LLC | 3.17% | 2.8M | $292.8M | -3.2% |
| State Street Corporation | 2.96% | 2.6M | $273.5M | +15.2% |
| Paradigm Biocapital Advisors LP | 2.23% | 2.0M | $205.3M | +33.4% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.